06 February 2026
06 February 2026
The upcoming patent cliff, the impact of geopolitical and policy issues, and a changing deal environment were discussed at the J. P. Morgan Healthcare Conference 2026.
After more than a year out in the cold, the programme’s reauthorisation is a boost for rare disease therapy developers.
FDA commissioner Marty Makary’s pledge came after Hims & Hers launched a compounded version of Novo’s Wegovy pill.
The site will act as a global hub for cancer research as the UK looks to maintain its competitiveness in the life sciences market.
The company projects 2026 revenues between $46.0bn and $47.5bn, with non-GAAP EPS ranging from $6.05 to $6.35.
Eisai will now take ownership of the Japanese rights to differentiated anti-PD-1 therapy, Hetronifly.
Apotex’s Searchlight Pharma will seek marketing authorisation and manage commercialisation activities for Nebido in Canada.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
